[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655880":3},{"organization":4,"outcomesModule":7,"designInfo":44,"detailedDescription":43,"studyPopulation":46,"armGroups":47,"interventions":55,"overallOfficials":70,"centralContacts":85,"locations":91,"responsibleParty":109,"collaborators":111,"id":117,"slug":118,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":124,"sex":125,"minAge":126,"maxAge":43,"enrollmentInfo":127,"targetDuration":43,"studyType":130,"phases":43,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":141,"whyStopped":43,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Chulalongkorn University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":43},[9,13],{"measure":10,"description":11,"timeFrame":12},"Prevalence of Headache","Number and percentage of participants who report headache in 1 year based on the structured online headache questionnaire.","At enrollment during the one-time online questionnaire",{"measure":14,"description":15,"timeFrame":12},"Clinical Characteristics of Headache","Number and percentage of participants reporting headache characteristics, including headache location, pain quality, aggravation by physical activity, nausea or vomiting, sensitivity to light, sensitivity to sound, aura symptoms, and reported headache triggers.",[17,20,24,27,30,33,36,39],{"measure":18,"description":19,"timeFrame":12},"Prevalence of Migraine","Number and percentage of participants who screen positive for migraine based on the ID Migraine and American Migraine Prevalence and Prevention\u002FAmerican Migraine Study questionnaires.",{"measure":21,"description":22,"timeFrame":23},"Headache-Related Disability Assessed Using the Migraine Disability Assessment Questionnaire","Headache-related disability measured using the total Migraine Disability Assessment (MIDAS) score. Higher scores indicate greater headache-related disability.","During the 3 months before enrollment",{"measure":25,"description":26,"timeFrame":12},"Association Between Gender-Affirming Hormone Therapy Use and Headache","Association between current or previous gender-affirming hormone therapy (GAHT) use and the presence of headache, as assessed by a self-reported headache item in the study questionnaire. The association will be estimated using logistic regression and reported as an odds ratio with a 95% confidence interval.\n\nUnit of Measure: Odds ratio",{"measure":28,"description":29,"timeFrame":12},"Association Between Gender-Affirming Surgery and Headache","Association between a history of gender-affirming surgery and the presence of headache, as assessed by a self-reported headache item in the study questionnaire. The association will be estimated using logistic regression and reported as an odds ratio with a 95% confidence interval.\n\nUnit of Measure: Odds ratio",{"measure":31,"description":32,"timeFrame":12},"Association Between HIV Pre-Exposure Prophylaxis Use and Headache","Association between current or previous HIV pre-exposure prophylaxis (PrEP) use and the presence of headache, as assessed by a self-reported headache item in the study questionnaire. The association will be estimated using logistic regression and reported as an odds ratio with a 95% confidence interval.\n\nUnit of Measure: Odds ratio",{"measure":34,"description":35,"timeFrame":12},"Association Between Gender-Affirming Hormone Therapy Use and Migraine","Association between current or previous gender-affirming hormone therapy (GAHT) use and the presence of migraine, assessed using the ID Migraine and American Migraine Prevalence and Prevention\u002FAmerican Migraine Study questionnaires.. The association will be estimated using logistic regression and reported as an odds ratio with a 95% confidence interval.\n\nUnit of Measure: Odds ratio",{"measure":37,"description":38,"timeFrame":12},"Association Between Gender-Affirming Surgery and Migraine","Association between a history of gender-affirming surgery and the presence of migraine, as assessed by the ID Migraine and American Migraine Prevalence and Prevention\u002FAmerican Migraine Study questionnaires. The association will be estimated using logistic regression and reported as an odds ratio with a 95% confidence interval.\n\nUnit of Measure: Odds ratio",{"measure":40,"description":41,"timeFrame":42},"Association Between HIV Pre-Exposure Prophylaxis Use and Migraine","Association between current or previous HIV pre-exposure prophylaxis (PrEP) use and the presence of migraine, as assessed by the ID Migraine and American Migraine Prevalence and Prevention\u002FAmerican Migraine Study questionnaires. The association will be estimated using logistic regression and reported as an odds ratio with a 95% confidence interval.\n\nUnit of Measure: Odds ratio","Time Frame: At enrollment during the one-time online questionnaire",null,{"allocation":43,"interventionModel":43,"interventionModelDescription":43,"primaryPurpose":43,"observationalModel":6,"timePerspective":45,"maskingInfo":43},"CROSS_SECTIONAL","The study population will consist of self-identified transgender adults in Thailand who currently attend or have previously attended the Tangerine Clinic at the Institute of HIV Research and Innovation in Bangkok, Thailand. Potential participants will be invited through online communication using contact information previously provided to the clinic or approached during a clinic visit. Interested individuals will access the study information, provide electronic informed consent, and complete the online questionnaire.",[48],{"label":49,"type":43,"description":50,"interventionNames":51},"Transgender Adults","Adults in Thailand who self-identify as transgender and currently attend or have previously attended the Tangerine Clinic in Bangkok. Participants will complete an online questionnaire about headache symptoms, migraine, gender-affirming care, and HIV pre-exposure prophylaxis use.",[52,53,54],"Drug: gender-affirming hormone therapy","Procedure: Gender-Affirming Surgery","Drug: HIV Pre-Exposure Prophylaxis",[56,61,66],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":43},"DRUG","gender-affirming hormone therapy","Current or previous use of gender-affirming hormone therapy as part of the participant's usual care. Information about medication name, dose, route, frequency, duration, and adherence will be collected through an online questionnaire. The researchers will not assign or modify hormone therapy.",[49],{"type":62,"name":63,"description":64,"armGroupLabels":65,"otherNames":43},"PROCEDURE","Gender-Affirming Surgery","History of gender-affirming surgery received as part of the participant's usual care. The type and date of surgery will be collected through an online questionnaire. No surgical procedure will be assigned or performed as part of this study.",[49],{"type":57,"name":67,"description":68,"armGroupLabels":69,"otherNames":43},"HIV Pre-Exposure Prophylaxis","Current or previous use of HIV pre-exposure prophylaxis as part of the participant's usual care. Information about PrEP use will be collected through an online questionnaire. The researchers will not prescribe or modify PrEP as part of this study.",[49],[71,74,77,80,82],{"name":72,"affiliation":5,"role":73},"Prakit Anukoolwittaya, M.D.","PRINCIPAL_INVESTIGATOR",{"name":75,"affiliation":76,"role":73},"Sirawit Roongrojwittayakul, M.D.","Ratchaburi Hospital",{"name":78,"affiliation":5,"role":79},"Akarin Hiransuthikul, M.D., M.Sc.","STUDY_DIRECTOR",{"name":81,"affiliation":5,"role":79},"Sekh Thanprasertsuk, M.D.",{"name":83,"affiliation":84,"role":79},"Jakkrapatara Boonruang, M.D.","Institute of HIV Research and Innovation",[86,90],{"name":72,"role":87,"phone":88,"phoneExt":43,"email":89},"CONTACT","0629141942","Prakit.A@chula.ac.th",{"name":75,"role":87,"phone":43,"phoneExt":43,"email":43},[92],{"facility":93,"status":43,"city":94,"state":43,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":103,"contacts":104},"Location Back to Contacts and Locations On this page, enter a location where the study is taking place.","Bangkok","10330","Thailand","TH",{"type":99,"coordinates":100},"Point",[101,102],100.50144,13.75398,{"lat":102,"lon":101},[105],{"name":106,"role":87,"phone":107,"phoneExt":43,"email":108},"Jakkrapatara Boonruang, MD","+66 2 160 5372","tangerineclinic@ihri.org",{"type":110,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR",[112,114],{"name":113,"class":6},"Institute of HIV Research and Innovation Foundation, Thailand",{"name":115,"class":116},"International Headache Society","UNKNOWN","100655880","headache-and-hormone-use-among-transgender-population-in-thailand-a-cross-sectional-online-study-100655880",false,"NCT07817446","Headache and Hormone Use Among Transgender Population in Thailand: A Cross-Sectional Online Study","H-TRANS","Inclusion Criteria:\n\n* Age 18 years or older\n* Self-identifies as transgender\n* Currently attends or has previously attended the Tangerine Clinic in Bangkok, Thailand\n* Able to understand the study information and provide electronic informed consent\n* Able to complete the online study questionnaire\n\nExclusion Criteria:\n\n* Alcohol or drug use, or a medical condition that, in the investigator's judgment, could interfere with completion of the study procedures or the ability to provide informed consent\n* A medical condition known to cause a secondary headache disorder unrelated to migraine, such as head trauma, a structural brain lesion, or an infection",true,"ALL","18 Years",{"count":128,"type":129},500,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn how common headache and migraine are and to describe headache patterns among transgender adults in Thailand. The main questions it aims to answer are:\n\n* How common are headache and migraine among transgender adults in Thailand?\n* What headache patterns and levels of headache-related disability do participants report?\n* Are gender-affirming hormone therapy, gender-affirming surgery, or HIV pre-exposure prophylaxis (PrEP) use related to headache or migraine?\n\nAbout 500 transgender adults aged 18 years or older who currently attend or previously attended the Tangerine Clinic in Bangkok, Thailand, will take part.\n\nParticipants will:\n\n* Provide consent online\n* Complete an online questionnaire about their general health and headache symptoms\n* Answer questions about gender-affirming hormone therapy, gender-affirming surgery, and PrEP use\n* Complete questionnaires that screen for migraine and measure how headaches affect daily activities\n\nThis study will not assign any treatment or change the participants' usual medical care.",[133,134],"Headache","Migraine",[136,137,138,63,67,139,140],"Transgender Persons","Gender Diverse Persons","Gender-Affirming Hormone Therapy","Headache Prevalence","Migraine Prevalence","NOT_YET_RECRUITING","2026-09-10",{"date":144,"type":145},"2026-09-14","ACTUAL",{"date":147,"type":129},"2026-11-01",{"date":149,"type":129},"2027-12-31",{"name":5,"class":6},1]